2-(氯甲基)-3-甲基喹唑啉-4(3H)-酮 | 199114-62-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-(氯甲基)-3-甲基喹唑啉-4(3H)-酮
• 英文名称: 2-(chloromethyl)-3-methylquinazolin-4(3H)-one
• 英文别名: 2-chloromethyl-3-methyl-4-oxo-3,4-dihydroquinazoline；2-(chloromethyl)-3-methylquinazolin-4-one
• CAS: 199114-62-0
• 化学式: C₁₀H₉ClN₂O
• mdl: MFCD07838408
• 分子量: 208.647
• InChiKey: NDYMABNTFFJQLH-UHFFFAOYSA-N

物化性质

• 熔点：
  185 °C(Solv: isopropanol (67-63-0))
• 沸点：
  337.4±44.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Chloromethyl)-3-methylquinazolin-4(3h)-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
H412: Harmful to aquatic life with long lasting effects
P273: Avoid release to the environment
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Chloromethyl)-3-methylquinazolin-4(3h)-one
CAS number: 199114-62-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H9ClN2O
Molecular weight: 208.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(氯甲基)-3-甲基喹唑啉-4(3H)-酮 在 硫酸 、 硝酸 作用下， 以85%的产率得到2-chloromethyl-3-methyl-6-nitroquinazolin-4(3H)-one
  参考文献：
  名称：

  新材料在水介质中的微波辅助合成 喹唑啉 衍生物作为抗癌药的前体

  摘要：

  快速，环保的微波辐射反应可实现新的2-取代基的“绿色合成” 喹唑啉通过水介质中的衍生物S-烷基化或来自的S RN 1反应2-氯甲基-3-甲基喹唑啉-4（3 H）-one 具有不同苯磺酸的衍生物和 亚硝酸盐 阴离子，在本文报道。

  DOI：

  10.1039/b816723k
• 作为产物：
  描述：

  2-氨基-N-甲基苯甲酰胺 以 吡啶 、 苯 为溶剂， 反应 8.0h， 生成 2-(氯甲基)-3-甲基喹唑啉-4(3H)-酮
  参考文献：
  名称：

  Reddy; Vasantha; Naga Raju, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1999, vol. 38, # 1, p. 40 - 44

  摘要：

  DOI：

文献信息

• [EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
  申请人：GLAXO GROUP LTD

  公开号：WO2011012622A1

  公开（公告）日：2011-02-03

  The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

  本发明涉及苯并噁唑酮衍生物，其制备方法，含有它们的药物组合物和药物，以及它们在治疗由GlyT1介导的疾病中的应用，包括神经系统和神经精神疾病，特别是精神病、痴呆或注意力缺陷障碍。
• Therapeutic uses of tri-aryl acid derivatives
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US07005440B1

  公开（公告）日：2006-02-28

  The use of triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

  使用公式（I）的三芳基酸衍生物及其药物组合物作为PPAR配体受体结合物。本发明的PPAR配体受体结合物可用作PPAR受体的激动剂或拮抗剂。
• Design, synthesis and <i>in vitro</i> biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment
  作者：Yi Le、Yiyuan Gan、Yihong Fu、Jiamin Liu、Wen Li、Xue Zou、Zhixu Zhou、Zhenchao Wang、Guiping Ouyang、Longjia Yan

  DOI：10.1080/14756366.2020.1715389

  日期：2020.1.1

  ne derivatives was designed, synthesised and evaluated for antitumor activity in vitro on wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK) and three human cancer cell lines including A549, PC-3, and SMMC-7721. The results displayed that some of the compounds had good activities, especially 2-4-[(3-Fluoro-phenylimino)-methyl]-phenoxymethyl}-3-methyl-3H-quinazolin-4-one (5 g),

  本文设计，合成了一系列新型3-甲基-喹唑啉酮衍生物，并评估了它们对野生型表皮生长因子受体酪氨酸激酶（EGFRwt-TK）和三种人类癌细胞系（包括A549，PC- 3，SMMC-7721。结果表明，某些化合物具有良好的活性，特别是2- 4-[（3-氟-苯基亚氨基）-甲基]-苯氧基甲基} -3-甲基-3H-喹唑啉-4-酮（5 g），2 -4-[（3,4-二氟-苯基亚氨基）-甲基]-苯氧基甲基} -3-甲基-3H-喹唑啉-4-酮（5k）和2- 4-[（3,5-二氟-苯基亚氨基） ）-甲基]-苯氧基甲基} -3-甲基-3H-喹唑啉-4-酮（5μl）对三种癌细胞具有很高的抗肿瘤活性。此外，化合物5k可以在高浓度下诱导A549细胞的晚期凋亡，并在测试浓度下阻止G2 / M期的A549细胞的细胞周期。同样，化合物5k可以抑制EGFRwt-TK，IC50值为10 nM。分子对接数据表明，化合物5k可
• Design, synthesis, biological activities and 3D-QSAR studies of quinazolinone derivatives containing hydrazone structural units
  作者：Li-Hui Shao、Si-Li Fan、Ying-Fen Meng、Yi-Yuan Gan、Wu-Bin Shao、Zhen-Chao Wang、Dan-Ping Chen、Gui-Ping Ouyang

  DOI：10.1039/d0nj05450j

  日期：——

  In this study, three series of quinazolinone derivatives containing hydrazone structures were designed and synthesized. Bioactivity assays indicated that these compounds showed good antitumour activities towards human lung cancer cells (A549) and human prostate cancer cells (PC-3) and no apparent toxicity towards those nontumorigenic rat renal tubular epithelial cells (NRK-52E). In particular, compound

  在这项研究中，设计并合成了三个系列的containing结构的喹唑啉酮衍生物。生物活性测定表明，这些化合物对人肺癌细胞（A549）和人前列腺癌细胞（PC-3）具有良好的抗肿瘤活性，对那些非致瘤性大鼠肾小管上皮细胞（NRK-52E）没有明显的毒性。特别地，化合物7n显示出对A549和PC-3的有效抑制活性，IC 50分别为7.36和7.73μmolL -1。随后，讨论了化合物结构与众多生物学活性之间的关系。一个好的预测三维定量构效关系（3D-QSAR）模型构建通过CoMFA指导未来的结构单位。目前的结果强烈表明，引入2-氟苯甲酰基的7n应被视为开发新型抗肿瘤药的先导化合物。
• RADIOLABELED PDE10A LIGANDS
  申请人：AbbVie Inc.

  公开号：US20130343992A1

  公开（公告）日：2013-12-26

  Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compound of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  公式（I）的化合物已被披露。这些公式（I）的化合物在治疗由PDE10A配体预防或缓解的疾病和疾病中起作用。公式（I）的放射标记化合物也可作为PDE10A正电子发射断层扫描配体的诊断工具。还披露了包括公式（I）化合物的药物组合物、使用这些化合物和组合物的方法，以及制备公式（I）范围内化合物的过程。